Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
Rhea-AI Summary
Sonoma Pharmaceuticals (NASDAQ:SNOA) priced a firm-commitment public offering expected to raise approximately $4.0 million gross. The offering includes 2,962,963 shares of common stock and 2,962,963 warrants at a purchase and exercise price of $1.35 each.
The company granted Dawson James Securities a 45-day overallotment option for up to 15% of the shares or warrants. Closing is expected on April 27, 2026. The company expects to use net proceeds for general corporate purposes, including working capital. A Form S-1 was declared effective on April 23, 2026.
Positive
- Expected gross proceeds of $4.0 million
- Net proceeds designated for general corporate purposes, including working capital
Negative
- Issuance of 2,962,963 shares and matching warrants creates immediate dilution
- Underwriter has a 45-day option to cover up to 15% overallotments, increasing potential dilution
News Market Reaction – SNOA
In the Apr 24 session, SNOA declined 36.67%, reflecting a significant negative market reaction. Argus tracked a peak move of +15.3% during that session. Argus tracked a trough of -55.0% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 23.7x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Retail product launch | Positive | -8.2% | U.S. retail launch of HOCl burn relief hydrogel in CVS and Walmart. |
| Mar 18 | Dermatology launch | Positive | +2.9% | Launch of Aquanil AD HOCl dermatology line for sensitive skin OTC. |
| Feb 10 | Earnings results | Positive | +1.4% | Q3 2026 results showing revenue growth and improved gross margin, smaller loss. |
| Jan 28 | Board changes | Neutral | -1.5% | Board refresh and new SVP for regulatory, quality and product development. |
| Nov 13 | Product recognition | Positive | -3.8% | Reliefacyn hydrogel earning National Rosacea Society Seal of Acceptance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows multiple instances where seemingly positive commercial or validation news coincided with negative next-day price reactions, suggesting a tendency for the stock to sell off on good news.
Over the last few months, Sonoma reported revenue growth and product expansion while navigating funding needs. On Feb 10, 2026, Q3 revenue rose to $4.3M with improved margins and a modestly narrower loss. Subsequent launches of new HOCl-based dermatology and burn products in March 2026, including retail rollouts at CVS and Walmart, produced mixed price reactions. Certification milestones in Nov 2025 and board/leadership changes in Jan 2026 also saw muted to negative moves, framing today’s financing announcement against a backdrop of operational progress but market skepticism.
Key Terms
hypochlorous acid medical
warrants financial
over-allotments financial
form s-1 regulatory
prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOULDER, CO / ACCESS Newswire / April 24, 2026 / Sonoma Pharmaceuticals, Inc. (the "Company" or "Sonoma Pharmaceuticals") (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the pricing of its public offering made on a firm commitment basis with gross proceeds to the Company expected to be approximately
In addition, Sonoma Pharmaceuticals has granted Dawson James Securities a 45-day option to purchase up to
The offering is expected to close on April 27, 2026, subject to the satisfaction of customary closing conditions.
The Company expects to use the net proceeds from the offering for general corporate purposes, including working capital.
Dawson James Securities is acting as sole bookrunner for the offering.
A registration statement on Form S-1 relating to the offering of the securities was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on April 23, 2026. The offering is being made only by means of a prospectus. A final prospectus describing the terms of the proposed transaction may be obtained, when available, on the SEC's website, www.sec.gov or by contacting Dawson James Securities. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, the ability to meet a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire